Biocon Biologics in South Africa
Biocon Biologics is a unique, fully integrated, global biosimilars company with world-class ‘lab-to-market’ capabilities across development, manufacturing, and marketing. It is present in over 120 countries, including over 80 Emerging Market countries, where it is providing sustainable solutions for a healthier world through its cost-effective, high-quality biosimilars.
Expanding Access to Lifesaving Therapies in AFMET
In the Africa-Midde East, Turkey (AFMET) region, Biocon Biologics is making a significant impact on patients’ lives by expanding access to lifesaving treatments and life-improving therapies to treat diseases like diabetes, cancer, and autoimmune conditions through its 6 commercialized biosimilars.
Biocon Biologics has developed a differentiated portfolio of biosimilars spanning insulins, monoclonal antibodies and conjugated recombinant proteins by leveraging its deep experience in biotechnology. It addresses the needs of patients in the AFMET region through its state-of-the-art manufacturing infrastructure, which includes facilities for producing monoclonal antibodies in Bengaluru, India.
Focused on Making a Meaningful Difference in South Africa
Through its self-led and partner-led commercial models, the company is focused on broadening access to biosimilars for treating cancer, diabetes and autoimmune disease for the benefit of patients and improving healthcare outcomes in South Africa. Biocon Biologics has six commercialized products in South Africa — Ogivri (Trastuzumab), Cipla Trastuzumab (Trastuzumab), Abevmy (Bevacizumab), Fulphila (Pegfilgrastim), Bevamyl (Bevacizumab) and Pegfilgrastim Eurolab (Pegfilgrastim).
Headquartered in Bengaluru, global biosimilars leader Biocon Biologics has a longstanding presence in the industry, having invested over $1 billion in R&D and global-scale manufacturing over the past two decades. The integration of the global biosimilars business acquired from its long-term partner has further strengthened Biocon Biologics’ commercial presence in South Africa. As a trusted and reliable company, Biocon Biologics is poised to consolidate its leadership in biosimilars in South Africa, making a meaningful impact on patients’ lives.
In South Africa, Bevacizumab, Pegfilgrastim and Trastuzumab are commercialized by our team. In addition, Trastuzumab (Ogivri) is commercialized by our partner Cipla and Pegfilgrastim and Bevacizumab are commercialized by our partner Eurolab.
Commercialized Products
| Sl. No | Brand Name | Molecule Name | THERAPY AREA |
| 1 | Ogivri | Trastuzumab | Cancer |
| 2 | Abevmy | Bevacizumab | Cancer |
| 3 | Fulphila | Pegfilgrastim | Cancer |
| 4 | Bevamyl | Bevacizumab* | Cancer |
| 5 | Pegfilgrastim Eurolab | Pegfilgrastim* | Cancer |
| 6 | Cipla Trastuzumab | Trastuzumab** | Cancer |
*Commercialized by our partner Eurolab in South Africa
**Commercialized by our partner Cipla in South Africa
Meet the Leaders
Delivering Highest-Quality Products Globally
80+
03
90+
Our Vision & Values
- Value creation through innovation and differentiation
- Collaboration, teamwork and mutual respect
- Performance-driven work culture
- Quality through compliance and best practices
- Integrity and ethical behaviour
The Biocon Advantage
*19th Annual Report of BioPlan Associates
